Hi Steve, great find! I haven't had a chance yet to read through the link but this could really be huge news for SciClone's longer term prospects vis-a-vis partnership agreements, etc. Remember that the value of a company like SciClone is so dependent on the value of its substance and use patents and this could potentially be huge (though again I haven't yet read through it). Sno, in terms of contacting Dr. Goldstein, that's an excellent idea but I'll have to think about it. I hate to bother him, and while I am legitimately interested in the thymosin beta-4 article in Nature I think I'd want to think about it first before calling. Thanks for the idea, though. I agree that Dr. Goldstein likely is still very interested in thymosin alpha-1 and in SciClone, too...I think the value of SciClone as a company just went up thanks to the pending patent published today in US for conjugated forms of thymosin alpha-1...How about a press release from the company?